Select Page

Cancer Drug Pipeline Information for Patient Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained on this website is not a comprehensive list. While we make reasonable efforts to present current and accurate information on this website, this website could include inaccuracies or typographical errors. We do not guarantee and are not responsible for the quality, currency, propriety, accuracy, or reasonableness of any information on this website. Please contact info@canceraction.ca with any inquiries about the terms of use.

Brand NameGeneric NameManufacturerTumour SiteIndicationRoute of AdministrationInformation Source
MasivetmasitinibAB ScienceGastrointestinalRelapsed metastatic colorectal cancerOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalMetastatic pancreatic cancerOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalGastrointestinal stromal tumour, first-line treatmentOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceMelanomaMetastatic melanoma with JM mutation of c-KITOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGastrointestinalGastrointestinal stromal tumour, second-line treatmentOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGynecologyRelapsed advanced / metastatic epithelial ovarian cancer patients in second line refractory to first line platinum treatment or in third lineOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceGenitourinaryMetastatic Castrate Resistant Prostate Cancer in first lineOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
MasivetmasitinibAB ScienceLymphomaRelapsed or refractory peripheral T-cell lymphomaOralhttp://www.ab-science.com/en/human-medicine/masitinib-in-oncology
VenclextavenetoclaxAbbVieLeukemiaChronic lymphocytic leukemia (CLL), relapsed-refractory and first lineOralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaAcute Myeloid Leukemia (AML)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaFollicular Lymphoma (FL)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieLeukemiaDiffuse Large B-Cell Lymphoma (DLBCL)Oralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
VenclextavenetoclaxAbbVieMyelomaMultiple myelomaOralhttps://www.abbvie.com/our-science/pipeline/venclexta.html
veliparibAbbVieLungOvarian cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
veliparibAbbVieBreastBreast cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
veliparibAbbVieLungLung cancerOralhttps://www.abbvie.com/our-science/pipeline/veliparib.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer, third lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer, first lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer,second lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieGastrointestinalPancreatic cancerOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLeukemiaAcute myeloid leukemia (AML)Oralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieMyelomaMultiple myelomaOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaMarginal zone lymphoma (MZL), relapsed/refractoryOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaDiffuse large B-cell lymphomaOralhttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaFollicular lymphomaOralhttps://www.abbvie.com/our-science/pipeline.html
EmplicitielotuzumabAbbVieMyelomaMultiple myeloma treatment naïveIntravenoushttps://www.abbvie.com/our-science/pipeline.html
EmplicitielotuzumabAbbVieMyelomaMultiple myeloma second lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
depatuxizumab mafodotinAbbVieNeurologicalGlioblastoma MultiformeIntravenoushttps://www.abbvie.com/our-science/pipeline.html
Imlygictalimogene laherparepvecAmgenMelanomaMid to late-stage metastatic melanomaSubcutaneoushttp://www.amgenpipeline.com/pipeline/
VectibixpanitumumabAmgenGastrointestinalChemorefractory, wild-type KRAS exon 2 metastatic colorectal cancerIntravenoushttp://www.amgenpipeline.com/pipeline/
XgevadenosumabAmgenOtherAdults and skeletally-mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to reult in severe morbiditySubcutaneoushttp://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
KyproliscarfilzomibAmgenMyelomaMultiple myeloma, in combination with chemotherapyIntravenoushttp://www.amgenpipeline.com/pipeline/
KyproliscarfilzomibAmgenLungSmall-cell lung cancerIntravenoushttp://www.amgenpipeline.com/pipeline/
BlincytoblinatumomabAmgenLymphomaDiffuse large B cell lymphoma (DLBCL)Intravenoushttp://www.amgenpipeline.com/pipeline/
BlincytoblinatumomabAmgenLeukemiaRelapsed/refractory Philadelphia chromosone-positive (Ph+) and minimal residual disease of acute lymphoblastic leukemiaIntravenoushttp://www.amgenpipeline.com/pipeline/
IclusigponatinibAriad PharmaceuticalsLeukemiaChronic-Phase Chronic Myeloid Leukemia (CP-CML), second lineOralhttp://www.ariad.com/research-development/clinical-trials/
brigatinibAriad PharmaceuticalsLungALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with crizotinibOralhttp://www.ariad.com/research-development/clinical-trials/
brigatinibAriad PharmaceuticalsLungALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously been treated with an ALK inhibitorOralhttp://www.ariad.com/research-development/clinical-trials/
encorafenibArray BioPharmaMelanomaBRAF-mutant melanoma in combination with binimetinibOralhttp://www.arraybiopharma.com/product-pipeline/encorafenib-lgx818/
encorafenibArray BioPharmaGastrointestinalBRAF-mutant colorectal cancer in combination with binimetinib and cetuximabOralhttp://www.arraybiopharma.com/product-pipeline/encorafenib-lgx818/
binimetinibArray BioPharmaGastrointestinalBRAF-mutant colorectal cancer, in combination with encorafenib and cetuximabOralhttp://www.arraybiopharma.com/product-pipeline/binimetinib/
binimetinibArray BioPharmaMelanomaBRAF-mutant melanoma in combination with encorafenibOralhttp://www.arraybiopharma.com/product-pipeline/binimetinib/
IMAB362Astellas PharmaGastrointestinalGastroesophageal adenocarcinomaIntravenoushttps://www.astellas.com/en/ir/library/medical.html
gilteritinib (ASP2215)Astellas PharmaLeukemiaAcute myeloid leukemiaOralhttps://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf
enfortumab vetodinAstellas PharmaGenitourinaryUrothelial cancerIntravenoushttps://www.astellas.com/en/ir/library/medical.html
ASG-16C3FAstellas PharmaGenitourinaryRenal cell carcinomaIntravenoushttps://www.astellas.com/en/ir/library/medical.html
selumetinibAstraZenecaEndocrineDifferentiated Thyroid CancerOralhttps://www.astrazeneca.com/our-science/pipeline.html
savolitinib/ volitinibAstraZenecaGenitourinaryPapillary renal cell carcinomahttps://www.astrazeneca.com/our-focus-areas/oncology.html
TagrissoosimertinibAstraZenecaLungBrain metastases in advanced EGRFm NSCLCOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
TagrissoosimertinibAstraZenecaLungAdjuvant EGRFm NSCLCOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
TagrissoosimertinibAstraZenecaLungfirst line advanced EGRFm NSCLCOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGenitourinaryProstate cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGynecologyFirst line BRCAm ovarian cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaBreastmBRCA adjuvant breast cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaBreastmBRCA metastatic breast cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGastrointestinalPancreatic cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
moxetumomab pasudotoxAstraZenecaLeukemiaHairy cell leukaemiaIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
MEDI-573AstraZenecaBreastMetastatic breast cancerhttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalGastric cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalMetastatic pancreatic ductal carcinomaIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalHepatocellular carcinomaIntravenoushttps://www.astrazeneca.com/our-science/pipeline.html
durvalumab + tremelimumabAstraZenecaLung3rd-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaLung1st-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGenitourinary1st-line bladder cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaHead and Neck2nd-line SCCHNIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaHead and Neck1st-line SCCHNIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
ImfinzidurvalumabAstraZenecaHead and NeckSquamous cell carcinoma of the head and neckIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
ImfinzidurvalumabAstraZenecaLungStage III NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
ImfinzidurvalumabAstraZenecaLung1st-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
ImfinzidurvalumabAstraZenecaGenitourinaryAdvanced bladder cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
ImfinzidurvalumabAstraZenecaGenitourinaryTreatment of locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemo or who have disease progression within 12 mo. of neoadjuvant or adjuvant treatment with platinum-containing chemoIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm
cediranibAstraZenecaGynecologyRecurrent platinum resistant ovarian cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
AZD6738AstraZenecaGastrointestinalGastric cancer, in combination with olaparibhttps://www.astrazeneca.com/our-focus-areas/oncology.html
AZD5363AstraZenecaBreastBreast cancerhttps://www.astrazeneca.com/our-focus-areas/oncology.html
AZD1775AstraZenecaGynecologyOvarian cancer, in combination with chemotherapyhttps://www.astrazeneca.com/our-focus-areas/oncology.html
acalabrutinibAstraZenecaLymphomaB-cell malignancyOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
acalabrutinibAstraZenecaLeukemiaFirst-line chronic lymphocytic leukemiaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
acalabrutinibAstraZenecaLeukemiaHigh-risk relapsed/refractory chronic lymphocytic leukemiaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
acalabrutinibAstraZenecaLeukemiaFirst-line mantle cell lymphomaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
NimoralnimorazoleAzanta A/SHead and NeckFirst-line platinum-resistent head and neck squamous cell carcinomaOralhttp://www.azanta.com/pipeline.aspx
NimoralnimorazoleAzanta A/SHead and NeckHead and neck squamous cell carcinoma, second line re-irradiation, accelerated or conventinal chemo-radiation therapy (CRT)Oralhttp://www.azanta.com/pipeline.aspx
NimoralnimorazoleAzanta A/SHead and NeckHead and neck squamous cell carcinoma, first line accelerated chemo-radiation therapy (CRT)Oralhttp://www.azanta.com/pipeline.aspx
StivargaregorafenibBayerGastrointestinaladjuvant therapy for colorectal cancerOralhttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
Radium-223 dichlorideBayerBreastbone metastasis in breast cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
Radium-223 dichlorideBayerGenitourinaryCastration-resistant prostate cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
darolutamideBayerGenitourinaryCastration-resistant prostate cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
darolutamideBayerGenitourinaryhormone sensitive prostate cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
AliqopacopanlisibBayerLymphomaDiffuse large B cell lymphoma (DLBCL)Intravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
AliqopacopanlisibBayerLymphomaNon Hodgkin LymphomaIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
AliqopacopanlisibBayerLymphomarelapsed follicular lymphomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm576098.htm
anetumab ravtansine BayerLungMalignant pleural mesotheliomaIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
xentuzumabBoehringer IngelheimBreastMetastatic breast cancer (oestrogen-receptor positive)https://www.inoncology.com/our-compounds
xentuzumabBoehringer IngelheimGenitourinaryCastration-resistant prostate cancerhttps://www.inoncology.com/our-compounds
VargatefnintedanibBoehringer IngelheimOtherUnresectable malignant pleural mesothelioma, in combination with pemetrexed/cisplatinOralhttps://www.inoncology.com/thoracic-malignancies-clinical-trials
VargatefnintedanibBoehringer IngelheimLungAdvanced or recurrent non‑small cell lung cancer patients after failure of first‑line therapy, in combination with pemetrexedOralhttps://www.inoncology.com/thoracic-malignancies-clinical-trials
VargatefnintedanibBoehringer IngelheimLungStage IIIB/IV or recurrent non‑small cell lung cancer (NSCLC) after failure of first‑line chemotherapy, in combination with docetaxelOralhttps://www.inoncology.com/thoracic-malignancies-clinical-trials
BI 836858Boehringer IngelheimLeukemiaAcute Myeloid Leukemiahttps://www.inoncology.com/our-compounds
BI 836858Boehringer IngelheimLeukemiaMyelodysplastic syndromehttps://www.inoncology.com/our-compounds
BI 836826Boehringer IngelheimLymphomaNon-Hodgkin lymphomahttps://www.inoncology.com/our-compounds
BI 836826Boehringer IngelheimLeukemiaChronic lymphocytic leukemiahttps://www.inoncology.com/our-compounds
GiotrifafatinibBoehringer IngelheimLungSquamous Cell Lung Cancer After at Least One Prior Platinum-Based ChemotherapyOralhttps://www.inoncology.com/nsclc-afatinib-clinical-trials
GiotrifafatinibBoehringer IngelheimLungNon-small cell lung cancer after failure of erlotinib or gefitinibOralhttps://www.inoncology.com/nsclc-afatinib-clinical-trials
GiotrifafatinibBoehringer IngelheimLungPatients with non-small cell lung cancer (NSCLC) who had failed at least one line of chemotherapy and erlotinib or gefitinib treatmentOralhttps://www.inoncology.com/nsclc-afatinib-clinical-trials
GiotrifafatinibBoehringer IngelheimHead and NeckRecurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum‑based therapyOralhttps://www.inoncology.com/compounds/afatinib/head-neck-cancer
GiotrifafatinibBoehringer IngelheimLungAdvanced NSCLC Harbouring HER2 Mutations, Previously Treated With ChemotherapyOralhttps://www.inoncology.com/nsclc-afatinib-clinical-trials
GiotrifafatinibBoehringer IngelheimGenitourinaryadvanced platinum-refractory urothelial cancerOralhttps://www.inoncology.com/compounds/afatinib/urothelial-carcinoma
OpdivonivolumabBristol-Myers SquibbGenitourinaryLocally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapyIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm539646.htm
OpdivonivolumabBristol-Myers SquibbGastrointestinalmismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) metastatic colorectal cancerIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569366.htm
OpdivonivolumabBristol-Myers SquibbGastrointestinalFDA granted accelerated approval to nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenibIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577166.htm
ThalomidthalidomideCelgeneMyelomaNewly diagnosed multiple myelomaOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
IstodaxromidepsinCelgeneLymphomaFirst-line peripheral T-cell lymphomaIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
IstodaxromidepsinCelgeneLymphomaCutaneous T-cell lymphomaIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
AbraxanepaclitaxelCelgeneGastrointestinalAdjuvant treatment for pancreatic cancerIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
oral azacitidine (CC-486)CelgeneOtherLower-risk myelodysplastic syndromeOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
oral azacitidine (CC-486)CelgeneOtherMyelodysplastic syndromeOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
oral azacitidine (CC-486)CelgeneLungAdvanced non-small cell lung cancerOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
oral azacitidine (CC-486)CelgeneBreastMetastatic breast cancerOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
Abraxanenab-paclitaxelCelgeneGastrointestinalAdjuvant therapy for pancreatic cancerIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
marizomibCelgeneNeurologicalGlioblastoma multiformehttps://www.celgene.com/content/uploads/product-pipeline.pdf
luspaterceptCelgeneOtherMyleodysplastic syndromeSubcutaneoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
RevlimidlenalidomideCelgeneOtherMyelodysplastic syndrome - deletion 5qOralhttp://www.celgene.com/content/uploads/product-pipeline.pdf
RevlimidlenalidomideCelgeneLymphomaFirst-line diffuse large B-cell lymphoma (ABC-subtype)Oralhttp://www.celgene.com/content/uploads/product-pipeline.pdf
RevlimidlenalidomideCelgeneLymphomaRelapsed/refractory indolent lymphomaOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
RevlimidlenalidomideCelgeneLymphomaFirst-line follicular lymphomaOralhttps://www.celgene.com/content/uploads/product-pipeline.pdf
RevlimidlenalidomideCelgeneLymphomaMantle cell lymphoma (relapsed/refractory)Oralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm
IdhfaenasidenibCelgeneLeukemiarelapsed or refractory acute myeloid leukemia Oralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569482.htm
durvalumabCelgeneLeukemiaAcute myeloid leukemia (AML)Intravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
durvalumabCelgeneOtherMyleodysplastic syndromeIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
CC-486CelgeneLeukemiaPost-induction acute myeloid leukemia maintenanceIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
Vidazaazacitidine for injectionCelgeneLeukemiaAcute myeloid leukemia (20-30% blasts)Intravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
Vidazaazacitidine for injectionCelgeneLeukemiaAcute myeloid leukemia (>30% blastsIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
Vidazaazacitidine for injectionCelgeneOtherMyelodysplastic syndromesIntravenoushttps://www.celgene.com/content/uploads/product-pipeline.pdf
RubracarucaparibClovis OncologyGynecologyDeleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapiesOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm
MORAb-004EisaiMelanomaMelanomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGastrointestinalHepatocellular carcinomaOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGastrointestinalBiliary tract cancerOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGenitourinaryFirst-line renal cell carcinomaOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGenitourinaryin combination with everolimus, for advanced renal cell carcinoma following one prior anti-angiogenic therapyOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm
farletuzumabEisaiGynecologyPlatinum-sensitive ovarian cancerIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
HalaveneribulinEisaiGenitourinaryUnresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.Intravenous https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm483795.htm
HalaveneribulinEisaiSarcomaAdvanced soft tissue sarcomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
HalaveneribulinEisaiBreastBreast cancerIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
amatuximabEisaiLungMesotheliomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
CyramzaramucirumabEli LillyGastrointestinalMetastatic colorectal cancer, in combination with Folfiri, for patients whose disease has progressed on a first line bevacizumab, oxaliplatin, and fluoropyrimidine-containing regimenIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm
CyramzaramucirumabEli LillyGastrointestinalGastric cancer - Phase 3Intravenoushttp://lillyoncologypipeline.com/clinical-phase/III
CyramzaramucirumabEli LillyGastrointestinalSecond-line treatment in patients with hepatocellular carcinoma and elevated Baseline alpha-fetoprotein (AFP) following first-line therapy with sorafenibIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyGastrointestinalSecond-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma, in combination with paclitaxelIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyGastrointestinalAdvanced gastric or gastroesophageal junction adenocarcinoma, refractory to or progressive after first-line therapy with platinum and fluoropyrimidineIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyGastrointestinalMetastatic gastric or gastroesophageal junction adenocarcinomaIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyLungMetastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy, in combination with docetaxelIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm
CyramzaramucirumabEli LillyLungPreviously untreated patients with EGFR mutation-positive metastatic non-small cell lung cancerIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyGenitourinaryPatients with locally advanced or unresectable or metastatic urothelial carcinoma who progressed on or after platinum-based therapy, in combination with docetaxelIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
CyramzaramucirumabEli LillyLungStage IV non-small cell lung cancer following disease progression after prior platinum-based chemotherapy, in combination with weekly docetaxelIntravenoushttp://lillyoncologypipeline.com/molecule/vegf-receptor-2-antagonist/trials
ralimetinibEli LillyGynecologyOvarian cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
prexasertibEli LillyLungPatients with extensive-stage disease small cell lung cancer who have either platinum-sensitive or plantinum-resistant/refractory diseaseIntravenoushttp://lillyoncologypipeline.com/molecule/chk-1-inhibitor/trials
necitumumabEli LillyLungFirst-line stage IV squamous non-small cell lung cancerIntravenoushttp://lillyoncologypipeline.com/molecule/egfr-antibody/trials
merestinibEli LillyGastrointestinalFirst-line advanced or metastatic biliary tract cancerOralhttp://lillyoncologypipeline.com/molecule/met-inhibitor/trials
LY3023414Eli LillyLungNon-small cell lung cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
LY3023414Eli LillyGenitourinaryProstate cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
galunisertibEli LillyGastrointestinalHepatocellular CarcinomaOralhttp://lillyoncologypipeline.com/molecule/tgf-beta-r-1-kinase-inhibitor/trials
emibetuzumabEli LillyLungNon-small cell lung cancerIntravenoushttp://lillyoncologypipeline.com/clinical-phase/II
abemaciclibEli LillyGastrointestinalPancreatic cancerOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
abemaciclibEli LillyLungStage IV NSCLC with a detectable KRAS mutation who have progressed after platinum-based chemotherapyOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
abemaciclibEli LillyLungSquamous non-small cell lung cancerOralhttp://lillyoncologypipeline.com/clinical-phase/II
abemaciclibEli LillyBreastPostmenopausal women with hormone-receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancerOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
abemaciclibEli LillyBreastwith Trastuzumab for Hormone-Receptor-Positive, HER2-Positive Locally Advanced or Metastatic Breast CancerOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
abemaciclibEli LillyNeurologicalPatients with brain metastases secondary to hormone-receptor-positive breast cancer, non-small cell lung cancer, or melanomaOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
tepotinibEMD SeronoGastrointestinalHepatocellular cancerOralhttp://www.emdserono.com/en/research/Pipeline/research.html
tepotinibEMD SeronoLungNon-small cell lung cancerOralhttp://www.emdserono.com/en/research/Pipeline/research.html
avelumabEMD SeronoGastrointestinalFirst line gastric cancerIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
avelumabEMD SeronoGastrointestinalThird line gastric cancerIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
avelumabEMD SeronoGynecologyPlatinum resistant/refractory ovarian cancerIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
avelumabEMD SeronoGynecologyFirst line ovarian cancerIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
avelumabEMD SeronoHead and NeckLocally advanced head and neckIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
avelumabEMD SeronoOtherMerkel cell carcinomaIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
avelumabEMD SeronoLungFirst line non-small cell lung cancerIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
avelumabEMD SeronoLungSecond line non-small cell lung cancerIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
avelumabEMD SeronoGenitourinaryFirst line renal cell carcinomaIntravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
avelumabEMD SeronoGenitourinaryUrothelial cancer 1L1Intravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
avelumabEMD SeronoGenitourinaryUrothelial cancer 1L2Intravenoushttp://www.emdserono.com/en/research/Pipeline/research.html
BavencioavelumabEMD SeronoGenitourinaryFor patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm
CometriqcabozantinibExelixisGastrointestinalHepatocellular cancer, second lineOralhttp://www.exelixis.com/sites/default/files/pdf/Cabozantinib_Clinical_Trials-August_2017.pdf
CometriqcabozantinibExelixisSarcomaSoft tissue sarcomaOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisBreastBreast cancer patients with brain metastasesOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisBreastMetastatic, hormone-receptor positive breast cancer, with fulvestrantOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisLungNon-small cell lung cancer with molecular alterations in RET, ROS1, MET, AXL, or NTRK1Oralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisLungNon-small cell lung cancer: EGFR wild-typeOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGynecologyEndometrial cancerOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGynecologyHigh-grade uterine sarcomaOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisSarcomaRelapsed osteosarcoma or Ewing sarcomasOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisEndocrineDifferentiated thyroid cancerOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGenitourinaryMetastatic renal cell cancer. First-line, in combination with nivolumab +/- ipilimumabOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGenitourinaryAdvanced renal cell carcinoma: previously untreated, intermediate or poor-risk patientsOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisBreastTriple negative breast cancerOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGenitourinaryAdvanced hepatocellular cancer, in combination with nivolumab +/- ipilimumabOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGastrointestinalPancreatic neuroendocrine and carcinoid tumorsOralhttps://www.exelixis.com/lead-compounds/
CometriqcabozantinibExelixisGastrointestinalMetastatic gastrointestinal stromal tumorOralhttps://www.exelixis.com/lead-compounds/
ErivedgevismodegibGenentechOtherOperable basal cell carcinomaOralhttp://www.gene.com/medical-professionals/pipeline
Kadcylatrastuzumab emtansineGenentechBreast1st line HER2-positive metastatic breast cancerIntravenoushttp://www.gene.com/medical-professionals/pipeline
Kadcylatrastuzumab emtansineGenentechBreast3rd line HER2-positive metastatic breast cancerIntravenoushttp://www.gene.com/medical-professionals/pipeline
RITUXAN HYCELArituximab and hyaluronidase humanGenentechLeukemiafollicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemiaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564235.htm
polatuzumab vedotinGenentechLymphomaNon-Hodgkin's lymphoma and diffuse large B-cell lymphomaIntravenoushttp://www.gene.com/medical-professionals/pipeline
PerjetapertuzumabGenentechBreastEarly HER2-positive breast cancerIntravenoushttp://www.gene.com/medical-professionals/pipeline
PerjetapertuzumabGenentechBreast2nd line HER2-negative breast cancerIntravenoushttp://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLeukemiaFront-line chronic lymphocytic leukemiaIntravenoushttp://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLymphomaDiffuse large B-cell lymphomaIntravenoushttp://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLymphomaRefractory indolent non-Hodgkin's lymphomaIntravenoushttp://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechGastrointestinalGastric cancerOralhttp://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechBreastTriple-negative breast cancerOralhttp://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechGastrointestinalProstate cancerOralhttp://www.gene.com/medical-professionals/pipeline
AvastinbevacizumabGenentechNeurologicalFirst-line glioblastoma multiformeIntravenoushttp://www.gene.com/medical-professionals/pipeline
AvastinbevacizumabGenentechGynecologyRelapsed platinum-sensitive ovarian cancer Intravenoushttp://www.gene.com/medical-professionals/pipeline
TecentriqatezolizumabGenentechGenitourinaryFor locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chem or have disease progression within 12 mo's of neoadjuvant or adjuvant treatment with platinum-containing chemoIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm
tirabrutinibGilead SciencesLymphomaB-cell malignanciesOralhttp://www.gilead.com/research/pipeline
ZydeligidelalisibGilead SciencesLeukemiaRelapsed refractory chronic lymphocytic leukemiaOralhttp://www.gilead.com/research/pipeline
entospletinibGilead SciencesLeukemiaAcute Myeloid LeukemiaOralhttp://www.gilead.com/research/pipeline
entospletinibGilead SciencesLeukemiaHematological MalignanciesOralhttp://www.gilead.com/research/pipeline
andecaliximabGilead SciencesGastrointestinalGastric CancerSubcutaneoushttp://www.gilead.com/research/pipeline
VenclextavenetoclaxHoffmann-La RocheLeukemiaFrontline chronic lymphocytic leukemia, in combination with GazyvaOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiaRealpsed/refractory chronic lymphocytic leukemia, in combination with rituximabOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiamyelodysplastic syndromes, first-line treatmentOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheMyelomaRelapsed or refractory multiple myelomaOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLymphomaFront-line diffuse large B-cell lymphomaOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLymphomaRelapsed/refractory follicular lymphoma, in combination with rituximabOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiaAcute myelogenous leukemia, first-line treatmentOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ZelborafvemurafenibHoffmann-La RocheMelanomaAdjuvant melanoma, BRAF mutation positiveOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
vanucizumabHoffmann-La RocheGastrointestinalColorectal cancerhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastEarly HER2-positive breast cancer, adjuvant treatment, in combination with PerjetaIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastSecond line HER2-positive metastatic breast cancer, in combination with TecentriqIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastEarly HER2-positive breast cancer, adjuvant treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastThird line HER2-positive metastatic breast cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
taselisibHoffmann-La RocheBreastHER2-negative, hormone receptor-positive metastatic breast cancer, neoadjuvant treatmentOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
taselisibHoffmann-La RocheBreastHER2-negative, hormone receptor-positive metastatic breast cancetOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
RituxanrituximabHoffmann-La RocheLeukemiaChronic lymphocytic leukemiaSubcutaneoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
polatuzumab vedotinHoffmann-La RocheLeukemiaHematological malignanciesIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
PerjetapertuzumabHoffmann-La RocheGastrointestinalAdvanced HER2-positive gastric cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
PerjetapertuzumabHoffmann-La RocheBreastEarly HER2-positive breast cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
GazyvaobinutuzumabHoffmann-La RocheLymphomaFront-line indolent non-Hodgkin's lymphomaIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheBreastTriple-negative breast cancer, adjuvant treatmentOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheBreastTriple-negative breast cancer, first-line treatmentOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheGenitourinaryCastration-resistant prostate cancerOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
idasanutlinHoffmann-La RocheLeukemiaAcute myeloid leukemiaOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
codrituzumabHoffmann-La RocheGastrointestinalMetastatic liver cancerhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Cotellic + Tecentriq + Zelborafcobimetinib + atezolizumab + vemurafenibHoffmann-La RocheMelanomaBRAFv600 mutation-positive advanced melanoma, first-line treatmentOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CotelliccobimetinibHoffmann-La RocheGastrointestinalThird-line advanced or metastatic colorectal cancer, in combination with TecentriqOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CotelliccobimetinibHoffmann-La RocheBreastFirst line metastatic triple negative breast cancerOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
AvastinbevacizumabHoffmann-La RocheGynecologyRelapsed platinum-sensitive ovarian cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGynecologyOvarian cancer, front-line treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinarySecond-line urothelial bladder cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinary1st-line cis-ineligible and 2nd-line metastatic urothelial bladder cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous and squamous non-small cell lung cancer, PDL1-selected patientsIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungSecond-line non-small cell lung cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryRenal cell cancer, in combination with AvastinIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapy, with or without AvastinIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungMetastatic non-small cell lung cancer whose disease progressed during or following platinum-containing chemotherapyIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm525780.htm
TecentriqatezolizumabHoffmann-La RocheLungNon-small cell lung cancer, adjuvant treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line squamous non-small cell lung cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryMuscle-invasive bladder cancer, adjuvant treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryFirst-line cisplatin-ineligible metastatic urothelial carcinomaIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapyIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapy and pemetrexedIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst line extensive-stage small cell lung cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryRenal cell carcinoma, adjuvant treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheBreastMetastatic triple-negative breast cancer, first-line treatmentIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryCastration-resistant prostate cancerIntravenoushttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
AlecensaalectinibHoffmann-La RocheLungALK+ metastatic non-small cell lung cancer, first lineOralhttp://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
SomatulinelanreotideIpsen PharmaGastrointestinalUnresectable, well or moderately differentiated, locally, advanced or metastatic gastroenteropancreatic neuroendocrine tumorsSubcutaneoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427065.htm
YondelistrabectedinJanssenGynecologyRelapsed ovarian cancerIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLeukemiaFrontline chronic lymphocytic leukemia, in combination with obinutuzumabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLeukemiaFrontline chronic lymphocytic leukemia (young and fit), in combinaction with rituximabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaPatients with mantle cell lymphoma who have received at least one prior therapyOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm374857.htm
ImbruvicaibrutinibJanssenLymphomaTreatment naive patients with mantle cell lymphoma, in combination with Bendamustine and RituximabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaRelapsed/refractory indolent non-Hodgkin's lymphoma, in combination with bendamustine and rituximab or R-CHOPOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaNewly diagnosed non-germinal centre B-cell subtype of diffuse large B-cell lymphoma, in combination with R-CHOPOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaMarginal zone lymphoma in patients who have received at least one prior therapyOralhttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-ineligible patients, in combination with bortezomib, melphalan and prednisoneIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-ineligible patients, in combination with lenalidomide and low-dose dexamethasoneIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-eligible patients, in combination with velcade, thalidomide and dexamethasomeIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
apalutamide + abiraterone acetateJanssenGenitourinaryMetastatic castration-resistant chemotherapy-naïve prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
apalutamideJanssenGenitourinaryPre-metastatic, castration-resistant prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
apalutamideJanssenGenitourinaryMetastatic hormone-sensitive prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
apalutamideJanssenGenitourinaryLocalized prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
ZytigaabirateroneJanssenGenitourinaryNewly Diagnosed Hormone Naïve Metastatic Prostate Cancer Oralhttp://www.janssen.com/research-and-development/product-pipeline
Vyxeosliposome-encapsulated combination of daunorubicin and cytarabine Jazz PharmaceuticalLeukemianewly diagnosed high risk AMLIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569950.htm
KeytrudapembrolizumabMerckGastrointestinalEsophogeal cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGastrointestinalrecurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm
KeytrudapembrolizumabMerckGastrointestinalColorectal CancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGastrointestinalLiver cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGynecologyOvarian CancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckBreastBreast cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGynecologyRenal cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGenitourinaryProstate cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckHead and NeckNasopharyngeal cancerIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckHead and NeckRecurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapyIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm515627.htm
KeytrudapembrolizumabMerckMyelomaMultiple myelomaIntravenoushttp://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckLymphomaPrimary mediastinal primary B-cell lymphomaIntravenoushttp://www.merck.com/research/pipeline/home.html
KymriahtisagenlecleucelNovartisLeukemiaacute lymphoblastic leukemia Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574154.htm
OdomzosonidegibNovartisOtherlocally advanced basal cell carcinomaOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm
ribociclibNovartisBreastBreast cancer, in combination with Everolimus + Exemestane or in combination with fulvestrantOralhttps://www.novartisoncology.com/about-us/our-pipeline
FarydakpanobinostatNovartisMyelomaMultiple myeloma, in combination with bortezomib and dexamethasone, for patients who have received at least two prior regimens including bortezomib and an immunomodulatory agentOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm435339.htm
ArzerraofatumumabNovartisLeukemiaFor extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL)Intravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
LCL161NovartisLeukemiaLeukemiahttps://www.novartisoncology.com/about-us/our-pipeline
LCL161NovartisMyelomaMultiple myelomahttps://www.novartisoncology.com/about-us/our-pipeline
EGF816NovartisLungNon-small cell lung cancerOralhttps://www.novartisoncology.com/about-us/our-pipeline
capmatinibNovartisLungNon-small cell lung cancerOralhttps://www.novartisoncology.com/about-us/our-pipeline
buparlisibNovartisGastrointestinalGastroesophageal junction cancerOralhttps://www.novartisoncology.com/about-us/our-pipeline
buparlisibNovartisHead and NeckGlioblastoma multiformeOralhttps://www.novartisoncology.com/about-us/our-pipeline
buparlisibNovartisHead and NeckHead and neck cancerOralhttps://www.novartisoncology.com/about-us/our-pipeline
buparlisibNovartisBreastBreast cancerOralhttps://www.novartisoncology.com/about-us/our-pipeline
alpelisibNovartisLungNon-small cell lung cancerOralhttps://www.novartisoncology.com/about-us/our-pipeline
alpelisibNovartisHead and NeckHead and neck squamous cell carcinomaOralhttps://www.novartisoncology.com/about-us/our-pipeline
alpelisibNovartisBreastAdvanced Breast Cancer That Has Progressed on or After Treatment With an Aromatase InhibitorOralhttp://www.trials.novartis.com/en/clinical-trials/us-oncology/oncology/solar/solar-1/overview/
talazoparibPfizerBreastGermline BRCA-mutated metastatic breast cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
SutentsunitinibPfizerGenitourinaryRenal cell carcinoma adjuvantOralhttp://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerHead and NeckSquamous cell carcinoma of the head and neckOralhttp://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastHigh-risk early breast cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastEarly breast cancer in adjuvant settingOralhttp://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastFor the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy in combination with fulvestrantOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm487080.htm
lorlatinibPfizerLungALK non-small cell lung cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
inotuzumab ozogamicinPfizerLeukemiaAcute lymphocytic leukemiaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572133.htm
glasdegibPfizerLeukemiaAcute Myeloid Leukemia (AML)Oralhttp://www.pfizer.com/science/drug-product-pipeline
Mylotarggemtuzumab ozogamicinPfizerLeukemiaAcute Myeloid LeukemiaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574518.htm
XtandienzalutamidePfizerGastrointestinalHepatocellular carcinomaOralhttp://www.pfizer.com/science/drug-product-pipeline
XtandienzalutamidePfizerGenitourinaryNon-metastatic castration-resistant prostate cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
XtandienzalutamidePfizerGenitourinaryProstate cancer in patients with non-metastatic biochemical recurrenceOralhttp://www.pfizer.com/science/drug-product-pipeline
XtandienzalutamidePfizerGenitourinaryMetastatic hormone sensitive prostate cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
dacomitinibPfizerLungFirst-line EGFR-mutant non-small cell lung cancerOralhttp://www.pfizer.com/science/drug-product-pipeline
XalkoricrizotinibPfizerLungROS1-positive metastatic non-small cell lung cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm490391.htm
BosulifbosutinibPfizerLeukemiaChronic myelogenous leukemia, first lineOralhttp://www.pfizer.com/science/drug-product-pipeline
InlytaaxitinibPfizerGenitourinaryRenal cell carcinoma, in combinationOralhttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerMelanomaMetastatic Merkel Cell CarcinomaIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGenitourinaryUrothelial Carcinoma, second lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGynecologyPlatinum resistant/refractory ovarian cancerIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerHead and NeckLocally Advanced Squamous Cell Carcinoma of the Head and NeckIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGenitourinaryUrothelial Carcinoma, first lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGenitourinaryRenal cell carcinoma adjuvant, in combination with Keytruda (pembrolizumab)Intravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerLungNon small cell lung cancer, second lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerLungNon small cell lung cancer, first lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGynecologyOvarian cancer, first lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGastrointestinalGastric cancer, first lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGastrointestinalGastric cancer, third lineIntravenoushttp://www.pfizer.com/science/drug-product-pipeline
neratinibPuma Biotechnology Inc.Breastfor the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm567259.htm
SAR439684SanofiOtherAdvanced cutaneous squamous cell carcinomaIntravenoushttp://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx
SAR439684SanofiOtherAdvanced basal cell carcinomaIntravenoushttp://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx
SAR439684SanofiLungNSCLC, first lineIntravenoushttp://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx
isatuximabSanofiLeukemiaAcute Lymphoblastic LeukemiaIntravenoushttp://en.sanofi.com/Innovation/rd_portfolio/rd_portfolio.aspx
isatuximabSanofiLymphomaRelapsed refractory multiple myelomaIntravenoushttp://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx
tisotumab vetodinSeattle GeneticsGenitourinaryCervical cancerhttp://www.seattlegenetics.com/pipeline
denintuzumab mafodotinSeattle GeneticsLymphomaRelapsed diffuse large B-cell lymphoma (rituximab + chemotherapy +/− SGN-CD19A)Intravenoushttp://www.seattlegenetics.com/pipeline
denintuzumab mafodotinSeattle GeneticsLymphomaFrontline diffuse large B-cell lymphoma, in combination with chemotherapy) (planned)Intravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaFrontline Hodgkin lymphoma, in combination with chemotherapyIntravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaFrontline CD30-expressing mature T-cell lymphomas, in combination with chemotherapyIntravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaCD30-expressing cutaneous T-cell lymphomaIntravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaFrontline Hodgkin lymphoma in patients 60+Intravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab VedotinSeattle GeneticsLymphomaRelapsed CD30-expressing diffuse large B-cell lymphoma (rituximab + bendamustine +/− brentuximab vedotinIntravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaSecond-line Hodgkin lymphoma, in combination with nivolumabIntravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaRelapsed non-Hodgkin lymphoma, in combination with nivolumabIntravenoushttp://www.seattlegenetics.com/pipeline
BeleodaqbelinostatSpectrumLymphomaRelapsed or refractory peripheral T-cell lymphomaIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm403960.htm
sapanisertib (TAK-228)TakedaBreastBreast cancerOralhttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
sapanisertib (TAK-228)TakedaGynecologyEndrometrial CancerOralhttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
sapanisertib (TAK-228)TakedaGenitourinaryRenal CancerOralhttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
IclusigponatinibTakedaLeukemiaImatinib resistant chronic phase Chronic myelogenous leukemia (CML)Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
IclusigponatinibTakedaLeukemiaSecond-line chronic phase Chronic myelogenous leukemia (CML)Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
IclusigponatinibTakedaLeukemiaPh+Acute lymphoblastic leukemia (ALL)Oralhttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
pevonedistatTakedaLeukemiaHigh-risk myelodysplastic syndromeIntravenoushttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
NinlaroixazomibTakedaMyelomaRelapsed refractory multiple myeloma amyloidosisOralhttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
NinlaroixazomibTakedaMyelomaMultiple myeloma maintenance non SCTOralhttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
NinlaroixazomibTakedaMyelomaMultiple myeloma maintenance post SCTOralhttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
NinlaroixazomibTakedaMyelomaNewly diagnosed multiple myelomaOralhttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
AlunbrigbrigatinibTakedaLymphomaFollicular lymphoma ALK +NSCLCOralhttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
AdcetrisbrentuximabTakedaLymphomaFrontline HLIntravenoushttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
AdcetrisbrentuximabTakedaLymphomaFrontline MTCL - Mature T-cell lymphomaIntravenoushttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
AdcetrisbrentuximabTakedaLymphomaHL post TrsansplantIntravenoushttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
AdcetrisbrentuximabTakedaLymphomaRelapsed CTCLIntravenoushttps://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
ZejulaniraparibTesaro, Inc.Gynecologymaintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
UnituxindinutuximabUnited TherapeuticsNeurologicalHigh-risk neuroblastoma in combination with GM-CSF, IL-2 and 13-cis-retinoic acid, for pediatric patients who have achieved at least a partial response to prior first-line multiagent, multimodality therapyIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm437480.htm
GiotrifafatinibBoehringer IngelheimLungin Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the LungOralhttps://www.inoncology.com/compounds/afatinib/urothelial-carcinoma

YesNo